Information Provided By:
Fly News Breaks for October 17, 2019
Oct 17, 2019 | 06:58 EDT
BofA/Merrill analyst Geoff Meacham reinstated coverage of Alexion Pharmaceuticals with a Buy rating and $130 price target. "Noise" around complement competition has overshadowed Alexion's "strong" fundamentals, driven by its Soliris/Ultomiris franchise, Meacham tells investors in a research note. The analyst likes the stock's risk/reward profile given the company's "differentiated" growth and "discounted" valuation.
News For ALXN From the Last 2 Days
There are no results for your query ALXN